Phase 2 Study of Gemcitabine or Gemcitabine + Enzastaurin in Participants With Advanced or Metastatic Pancreatic Cancer

Completed · Phase 2

Conditions studied: Pancreatic Neoplasm

In brief

The purpose of this research study is to determine the effects and toxicity of gemcitabine alone or gemcitabine plus enzastaurin in participants with pancreatic cancer.

Key facts

Study ID

NCT00267020

Run by

Eli Lilly and Company

People needed

130

Starts

2005-12-01

Expected to finish

2008-05-01

Last updated by the study team

2020-08-31

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Diagnosis of adenocarcinoma of the pancreas.
• Pretreatment tumor specimen must be available.
• No prior chemotherapy immunotherapy, biological therapy, or hormonal therapy for pancreatic cancer, including 5-fluorouracil (5-FU) with radiation therapy.
• Prior radiation allowed.
• Ability to stop some types of anti-seizure medicines within 14 days of enrollment.

You may not qualify if…

• Endocrine pancreatic tumor or ampullary cancer.
• Central Nervous System (CNS) metastases.
• Inability to swallow tablets.
• 10% or greater weight loss over the 6 weeks before study entry.

Where it is running

• For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559), Mon - Fri, 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician — Dallas, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.